The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis

Nature Cell Biology

Volumn 16, Issue 8, 2014, Pages 717-727

  McAllister, Sandra S ^a,b,c   Weinberg, Robert A ^d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c HARVARD STEM CELL INSTITUTE   (United States)

^d WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 2; ANGIOSTATIN; CHEMOKINE RECEPTOR CXCR4; ENDOSTATIN; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH DIFFERENTIATION FACTOR 15; MONOCYTE CHEMOTACTIC PROTEIN 1; OSTEOPONTIN; PLACENTAL GROWTH FACTOR; PROSAPOSIN; PROTEIN LYSINE 6 OXIDASE; SOMATOMEDIN B; STROMAL CELL DERIVED FACTOR 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN A; VERSICAN; CYTOKINE; GROWTH PROMOTOR;

ANGIOGENESIS; BONE MARROW CELL; CANCER CELL LINE; CARCINOGENESIS; CELL PROLIFERATION; CELLULAR DISTRIBUTION; HUMAN; METASTASIS; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; STEM CELL MOBILIZATION; TUMOR MICROENVIRONMENT; ANIMAL; BIOLOGICAL MODEL; BONE MARROW; DISEASE COURSE; IMMUNOLOGY; MEMBRANE MICROPARTICLE; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SPLEEN; SYSTEMS BIOLOGY;

ANIMALS; BONE MARROW; CELL-DERIVED MICROPARTICLES; CYTOKINES; DISEASE PROGRESSION; GROWTH SUBSTANCES; HUMANS; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; SPLEEN; SYSTEMS BIOLOGY; TUMOR MICROENVIRONMENT;

EID: 84905381214     PISSN: 14657392     EISSN: 14764679     Source Type: Journal    
DOI: 10.1038/ncb3015     Document Type: Review

References (129)

1. Joyce, J. A. & Pollard, J. W. Microenvironmental regulation of metastasis. Nat. Rev. Cancer 9, 239-252 (2009).
2. Pietras, K. & Ostman, A. Hallmarks of cancer: interactions with the tumor stroma. Exp. Cell Res. 316, 1324-1331 (2010).
3. Allinen, M. et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 6, 17-32 (2004).
4. Chang, H. Y. et al. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol. 2, E7 (2004).
5. Finak, G. et al. Gene expression signatures of morphologically normal breast tissue identify basal-like tumors. Breast Cancer Res. 8, R58 (2006).
6. Casey, T. et al. Molecular signatures suggest a major role for stromal cells in development of invasive breast cancer. Breast Cancer Res. Treat. 114, 47-62 (2009).
7. Ma, X. J., Dahiya, S., Richardson, E., Erlander, M. & Sgroi, D. C. Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Res. 11, R7 (2009).
8. Zajicek, G. Cancer as a systemic disease. Med. Hypotheses 4, 193-207 (1978).
9. Redig, A. J. & McAllister, S. S. Breast cancer as a systemic disease: a view of metastasis. J. Intern. Med. 274, 113-126 (2013).
10. Dvorak, H. F. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. 315, 1650-1659 (1986).
11. Arwert, E. N., Hoste, E. & Watt, F. M. Epithelial stem cells, wound healing and cancer. Nat. Rev. Cancer 12, 170-180 (2012).
12. Coussens, L. M. & Werb, Z. Inflammation and cancer. Nature 420, 860-867 (2002).
13. De Visser, K. E., Eichten, A. & Coussens, L. M. Paradoxical roles of the immune system during cancer development. Nat. Rev. Cancer 6, 24-37 (2006).
14. Mantovani, A., Allavena, P., Sica, A. & Balkwill, F. Cancer-related inflammation. Nature 454, 436-444 (2008).
15. Grivennikov, S. I., Greten, F. R. & Karin, M. Immunity, inflammation, and cancer. Cell 140, 883-899 (2010).
16. Trinchieri, G. Cancer and inflammation: an old intuition with rapidly evolving new concepts. Annu. Rev. Immunol. 30, 677-706 (2012).
17. Kalluri, R. Basement membranes: structure, assembly and role in tumour angiogenesis. Nat. Rev. Cancer 3, 422-433 (2003).
18. Lech, M. & Anders, H. J. Macrophages and fibrosis: How resident and infiltrating mononuclear phagocytes orchestrate all phases of tissue injury and repair. Biochim. Biophys. Acta 1832, 989-997 (2013).
19. Polyak, K., Haviv, I. & Campbell, I. G. Co-evolution of tumor cells and their microenvironment. Trends Genet. 25, 30-38 (2009).
20. Marsh, T., Pietras, K. & McAllister, S. S. Fibroblasts as architects of cancer pathogenesis. Biochim. Biophys. Acta 1832, 1070-1078 (2012).
21. Bissell, M. J. & Radisky, D. Putting tumours in context. Nat. Rev. Cancer 1, 46-54 (2001).
22. Seruga, B., Zhang, H., Bernstein, L. J. & Tannock, I. F. Cytokines and their relationship to the symptoms and outcome of cancer. Nat. Rev. Cancer 8, 887-899 (2008).
23. Gao, D. & Mittal, V. The role of bone-marrow-derived cells in tumor growth, metastasis initiation and progression. Trends Mol. Med. 15, 333-343 (2009).
24. Hanahan, D. & Coussens, L. M. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21, 309-322 (2012).
25. Cuiffo, B. G. & Karnoub, A. E. Mesenchymal stem cells in tumor development: emerging roles and concepts. Cell Adh. Migr. 6, 220-230 (2012).
26. Shaked, Y., McAllister, S., Fainaru, O. & Almog, N. Tumor dormancy and the angiogenic switch: possible implications of bone marrow-derived cells. Curr. Pharm. Des. 19, 1-14 (2014).
27. Eash, K. J., Greenbaum, A. M., Gopalan, P. K. & Link, D. C. CXCR2 and CXCR4 antagonistically regulate neutrophil trafficking from murine bone marrow. J. Clin. Invest. 120, 2423-2431 (2010).
28. Martin, C. et al. Chemokines acting via CXCR2 and CXCR4 control the release of neutrophils from the bone marrow and their return following senescence. Immunity 19, 583-593 (2003).
29. Wright, D. E., Wagers, A. J., Gulati, A. P., Johnson, F. L. & Weissman, I. L. Physiological migration of hematopoietic stem and progenitor cells. Science 294, 1933-1936 (2001).
30. Kondo, M. et al. Biology of hematopoietic stem cells and progenitors: implications for clinical application. Annu. Rev. Immunol. 21, 759-806 (2003).
31. Christopher, M. J., Rao, M., Liu, F., Woloszynek, J. R. & Link, D. C. Expression of the G-CSF receptor in monocytic cells is sufficient to mediate hematopoietic progenitor mobilization by G-CSF in mice. J. Exp. Med. 208, 251-260 (2011).
32. Chow, A. et al. Bone marrow CD169+ macrophages promote the retention of hematopoietic stem and progenitor cells in the mesenchymal stem cell niche. J. Exp. Med. 208, 261-271 (2011).
33. Winkler, I. G. et al. Bone marrow macrophages maintain hematopoietic stem cell (HSC) niches and their depletion mobilizes HSCs. Blood 116, 4815-4828 (2010).
34. Shojaei, F. et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat. Biotechnol. 25, 911-920 (2007).
35. Shojaei, F. et al. Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature 450, 825-831 (2007).
36. McAllister, S. S. et al. Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell 133, 994-1005 (2008).
37. Elkabets, M. et al. Human tumors instigate granulin-expressing hematopoietic cells that promote malignancy by activating stromal fibroblasts in mice. J. Clin. Invest. 121, 784-799 (2011).
38. Kopp, H. G., Ramos, C. A. & Rafii, S. Contribution of endothelial progenitors and proangiogenic hematopoietic cells to vascularization of tumor and ischemic tissue. Curr. Opin. Hematol. 13, 175-181 (2006).
39. Purhonen, S. et al. Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growth. Proc. Natl Acad. Sci. USA 105, 6620-6625 (2008).
40. Orimo, A. et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121, 335-348 (2005).
41. Hattori, K. et al. Plasma elevation of stromal cell-derived factor-1 induces mobilization of mature and immature hematopoietic progenitor and stem cells. Blood 97, 3354-3360 (2001).
42. DeNardo, D. G. et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 1, 54-67 (2011).
43. Anders, H. J., Romagnani, P. & Mantovani, A. Pathomechanisms: homeostatic chemokines in health, tissue regeneration, and progressive diseases. Trends Mol. Med. 20, 154-165 (2014).
44. Karnoub, A. E. et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449, 557-563 (2007).
45. Kidd, S. et al. Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging. Stem Cells 27, 2614-2623 (2009).
46. Melani, C., Chiodoni, C., Forni, G. & Colombo, M. P. Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood 102, 2138-2145 (2003).
47. Serafini, P., Borrello, I. & Bronte, V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin. Cancer Biol. 16, 53-65 (2006).
48. Almand, B. et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J. Immunol. 166, 678-689 (2001).
49. Young, M. R., Wright, M. A., Vellody, K. & Lathers, D. M. Skewed differentiation of bone marrow CD34+ cells of tumor bearers from dendritic toward monocytic cells, and the redirection of differentiation toward dendritic cells by 1alpha, 25-dihydroxyvitamin D3. Int. J. Immunopharmacol. 21, 675-688 (1999).
50. Yang, L. et al. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 13, 23-35 (2008).
51. Swirski, F. K. et al. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science 325, 612-616 (2009).
52. Cortez-Retamozo, V. et al. Origins of tumor-associated macrophages and neutrophils. Proc. Natl Acad. Sci. USA 109, 2491-2496 (2012).
53. Cortez-Retamozo, V. et al. Angiotensin II drives the production of tumor-promoting macrophages. Immunity 38, 296-308 (2013).
54. Ugurel, S., Rappl, G., Tilgen, W. & Reinhold, U. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J. Clin. Oncol. 19, 577-583 (2001).
55. Holzer, G. et al. Concentration of vascular endothelial growth factor (VEGF) in the serum of patients with malignant bone tumors. Med. Pediatr. Oncol. 36, 601-604 (2001).
56. Poon, R. T. et al. Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study. Ann. Surg. 233, 227-235 (2001).
57. Van de Vijver, M. J. et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347, 1999-2009 (2002).
58. Rudland, P. S. et al. Prognostic significance of the metastasis- associated protein osteopontin in human breast cancer. Cancer Res. 62, 3417-3427 (2002).
59. Mor, G. et al. Serum protein markers for early detection of ovarian cancer. Proc. Natl Acad. Sci. USA 102, 7677-7682 (2005).
60. Tuck, A. B., Chambers, A. F. & Allan, A. L. Osteopontin overexpression in breast cancer: knowledge gained and possible implications for clinical management. J. Cell. Biochem. 102, 859-868 (2007).
61. Azmi, A. S., Bao, B. & Sarkar, F. H. Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review. Cancer Metastasis Rev. 32, 623-642 (2013).
62. Pucci, F. & Pittet, M. J. Molecular pathways: tumor-derived microvesicles and their interactions with immune cells in vivo. Clin. Cancer Res. 19, 2598-2604 (2013).
63. Peinado, H. et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat. Med. 18, 883-891 (2012).
64. Grange, C. et al. Microvesicles released from human renal cancer stem cells stimulate angiogenesis and formation of lung premetastatic niche. Cancer Res. 71, 5346-5356 (2011).
65. Fremder, E. et al. Tumor-derived microparticles induce bone marrow-derived cell mobilization and tumor homing: A process regulated by osteopontin. Int. J. Cancer 135, 270-281 (2014).
66. Zetter, B. R. Angiogenesis and tumor metastasis. Annu. Rev. Med. 49, 407-424 (1998).
67. Chambers, A. F., Groom, A. C. & MacDonald, I. C. Dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer 2, 563-572 (2002).
68. Fidler, I. J. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat. Rev. Cancer 3, 453-458 (2003).
69. Gupta, G. P. & Massague, J. Cancer metastasis: building a framework. Cell 127, 679-695 (2006).
70. Hiratsuka, S. et al. MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2, 289-300 (2002).
71. Hiratsuka, S., Watanabe, A., Aburatani, H. & Maru, Y. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat. Cell Biol. 8, 1369-1375 (2006).
72. Kaplan, R. N. et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438, 820-827 (2005).
73. Dawson, M. R., Duda, D. G., Chae, S. S., Fukumura, D. & Jain, R. K. VEGFR1 activity modulates myeloid cell infiltration in growing lung metastases but is not required for spontaneous metastasis formation. PLoS ONE 4, e6525 (2009).
74. Peinado, H., Lavotshkin, S. & Lyden, D. The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. Semin. Cancer Biol. 21, 139-146 (2011).
75. Erler, J. T. et al. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 15, 35-44 (2009).
76. Sceneay, J. et al. Primary tumor hypoxia recruits CD11b+/Ly6Cmed/Ly6G+ immune suppressor cells and compromises NK cell cytotoxicity in the premetastatic niche. Cancer Res. 72, 3906-3911 (2012).
77. Kim, S. et al. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 457, 102-106 (2009).
78. Sceneay, J., Smyth, M. J. & Moller, A. The pre-metastatic niche: finding common ground. Cancer Metastasis Rev. 32, 449-464 (2013).
79. Tsou, C. L. et al. Critical roles for CCR2 and MCP-3 in monocyte mobilization from bone marrow and recruitment to inflammatory sites. J. Clin. Invest. 117, 902-909 (2007).
80. Kang, S. Y. et al. Prosaposin inhibits tumor metastasis via paracrine and endocrine stimulation of stromal p53 and Tsp-1. Proc. Natl Acad. Sci. USA 106, 12115-12120 (2009).
81. Schelter, F. et al. Tumor cell-derived Timp-1 is necessary for maintaining metastasis-promoting Met-signaling via inhibition of Adam-10. Clin. Exp. Metastasis 28, 793-802 (2011).
82. Jung, T. et al. CD44v6 dependence of premetastatic niche preparation by exosomes. Neoplasia 11, 1093-1105 (2009).
83. Taranova, A. G. et al. Allergic pulmonary inflammation promotes the recruitment of circulating tumor cells to the lung. Cancer Res. 68, 8582-8589 (2008).
84. Esposito, M. & Kang, Y. Targeting tumor-stromal interactions in bone metastasis. Pharmacol. Ther. 141, 222-233 (2014).
85. Pantel, K., Brakenhoff, R. H. & Brandt, B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat. Rev. Cancer 8, 329-340 (2008).
86. Klein, C. A. Parallel progression of primary tumours and metastases. Nat. Rev. Cancer 9, 302-312 (2009).
87. Roy, L. D. et al. Collagen induced arthritis increases secondary metastasis in MMTV-PyV MT mouse model of mammary cancer. BMC Cancer 11, 365 (2011).
88. Naumov, G. N. et al. Persistence of solitary mammary carcinoma cells in a secondary site: a possible contributor to dormancy. Cancer Res. 62, 2162-2168 (2002).
89. Almog, N. Molecular mechanisms underlying tumor dormancy. Cancer Lett. 294, 139-146 (2010).
90. Mullen, C. A., Urban, J. L., Van Waes, C., Rowley, D. A. & Schreiber, H. Multiple cancers. Tumor burden permits the outgrowth of other cancers. J. Exp. Med. 162, 1665-1682 (1985).
91. Reilly, R. T. et al. HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice. Cancer Res. 60, 3569-3576 (2000).
92. Yan, H. H. et al. Gr-1+CD11b+ myeloid cells tip the balance of immune protection to tumor promotion in the premetastatic lung. Cancer Res. 70, 6139-6149 (2010).
93. Granot, Z. et al. Tumor entrained neutrophils inhibit seeding in the premetastatic lung. Cancer Cell 20, 300-314 (2011).
94. Gao, D. et al. Myeloid progenitor cells in the premetastatic lung promote metastases by inducing mesenchymal to epithelial transition. Cancer Res. 72, 1384-1394 (2012).
95. Castano, Z., Tracy, K. & McAllister, S. S. The tumor macroenvironment and systemic regulation of breast cancer progression. Int. J. Dev. Biol. 55, 889-897 (2011).
96. Kuznetsov, H. S. et al. Identification of luminal breast cancers that establish a tumor-supportive macroenvironment defined by proangiogenic platelets and bone marrow-derived cells. Cancer Discov. 2, 1150-1165 (2012).
97. Battinelli, E. M., Markens, B. A. & Italiano, J. E. Jr Release of angiogenesis regulatory proteins from platelet alpha granules: modulation of physiologic and pathologic angiogenesis. Blood 118, 1359-1369 (2011).
98. Nilsson, R. J. et al. Blood platelets contain tumor-derived RNA biomarkers. Blood 118, 3680-3683 (2011).
99. Gay, L. J. & Felding-Habermann, B. Contribution of platelets to tumour metastasis. Nat. Rev. Cancer 11, 123-134 (2011).
100. Italiano, J. E. Jr et al. Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood 111, 1227-1233 (2008).
101. Labelle, M. & Hynes, R. O. The initial hours of metastasis: the importance of cooperative host-tumor cell interactions during hematogenous dissemination. Cancer Discov. 2, 1091-1099 (2012).
102. Folkman, J. & Kalluri, R. Cancer without disease. Nature 427, 787 (2004).
103. Bateman, A. & Bennett, H. P. The granulin gene family: from cancer to dementia. Bioessays 31, 1245-1254 (2009).
104. Castano, Z. et al. Stromal EGF and IGF1 together modulate plasticity of disseminated triple negative breast tumors. Cancer Discov. 3, 922-935 (2013).
105. Erez, N., Truitt, M., Olson, P. & Hanahan, D. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-B-dependent manner. Cancer Cell 17, 135-147 (2010).
106. Bruzzese, F. et al. Local and systemic pro-tumorigenic effects of fibroblast-derived GDF15/MIC-1. Cancer Res. 74, 3408-3417 (2014).
107. Breit, S. N. et al. The TGF-beta superfamily cytokine, MIC-1/GDF15: a pleotrophic cytokine with roles in inflammation, cancer and metabolism. Growth Factors 29, 187-195 (2011).
108. Li, B. et al. Id1-induced IGF-II and its autocrine/endocrine promotion of esophageal cancer progression and chemoresistance-implications for IGF-II and IGF-IR-targeted therapy. Clin. Cancer Res. 20, 2651-2662 (2014).
109. Lippitz, B. E. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol. 14, e218-228 (2013).
110. Graus, F. & Dalmau, J. Paraneoplastic neuropathies. Curr. Opin. Neurol. 26, 489-495 (2013).
111. Taucher, S. et al. Impact of pretreatment thrombocytosis on survival in primary breast cancer. Thromb. Haemost. 89, 1098-1106 (2003).
112. Stone, R. L. et al. Paraneoplastic thrombocytosis in ovarian cancer. N. Engl. J. Med. 366, 610-618 (2012).
113. Calle, E. E. & Kaaks, R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat. Rev. Cancer 4, 579-591 (2004).
114. Baserga, R., Peruzzi, F. & Reiss, K. The IGF-1 receptor in cancer biology. Int. J. Cancer 107, 873-877 (2003).
115. Gupta, P. B. et al. Systemic stromal effects of estrogen promote the growth of estrogen receptor-negative cancers. Cancer Res. 67, 2062-2071 (2007).
116. Demicheli, R., Biganzoli, E., Boracchi, P., Greco, M. & Retsky, M. W. Recurrence dynamics does not depend on the recurrence site. Breast Cancer Res. 10, R83 (2008).
117. Retsky, M. W., Demicheli, R., Hrushesky, W. J., Baum, M. & Gukas, I. D. Dormancy and surgery-driven escape from dormancy help explain some clinical features of breast cancer. APMIS 116, 730-741 (2008).
118. Gertz, M. A. Current status of stem cell mobilization. Br. J. Haematol. 150, 647-662 (2010).
119. Ebos, J. M., Lee, C. R., Christensen, J. G., Mutsaers, A. J. & Kerbel, R. S. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc. Natl Acad. Sci. USA 104, 17069-17074 (2007).
120. Okazaki, T. et al. Granulocyte colony-stimulating factor promotes tumor angiogenesis via increasing circulating endothelial progenitor cells and Gr1+CD11b+ cells in cancer animal models. Int. Immunol. 18, 1-9 (2006).
121. Shaked, Y. et al. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 313, 1785-1787 (2006).
122. Shaked, Y. et al. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 14, 263-273 (2008).
123. Barcellos-Hoff, M. H. Does microenvironment contribute to the etiology of estrogen receptor-negative breast cancer? Clin. Cancer Res. 19, 541-548 (2013).
124. Ebos, J. M., Lee, C. R. & Kerbel, R. S. Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. Clin. Cancer Res. 15, 5020-5025 (2009).
125. Guthrie, G. J. et al. The systemic inflammation-based neutrophil-lymphocyte ratio: Experience in patients with cancer. Crit. Rev. Oncol. Hematol. 88, 218-230 (2013).
126. Absenger, G. et al. A derived neutrophil to lymphocyte ratio predicts clinical outcome in stage II and III colon cancer patients. Br. J. Cancer 109, 395-400 (2013).
127. Stotz, M. et al. Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. Br. J. Cancer 109, 416-421 (2013).
128. Ishizuka, M., Nagata, H., Takagi, K., Iwasaki, Y. & Kubota, K. Combination of platelet count and neutrophil to lymphocyte ratio is a useful predictor of postoperative survival in patients with colorectal cancer. Br. J. Cancer 109, 401-407 (2013).
129. McMillan, D. C. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat. Rev. 39, 534-540 (2012).